Therapeutic drug monitoring of posaconazole delayed release tablet while managing COVID-19-associated mucormycosis in a real-life setting.

Patel, Atul; Patel, Ketan; Patel, Kamlesh; Shah, Kinjal; Chakrabarti, Arunaloke

Patel, Atul; Patel, Ketan; Patel, Kamlesh; Shah, Kinjal; Chakrabarti, Arunaloke.

Afiliação

Patel A; Infectious Diseases Department, Sterling Hospital, Ahmedabad, India.
Patel K; Infectious Diseases Department, Sterling Hospital, Ahmedabad, India.
Patel K; Department of Microbiology, Sterling Hospital, Ahmedabad, India.
Shah K; Infectious Diseases Department, Sterling Hospital, Ahmedabad, India.
Chakrabarti A; Department of Medical Microbiology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.

Mycoses ; 65(3): 312-316, 2022 Mar.

Article em En | MEDLINE | ID: mdl-34953080

Assuntos

COVID-19; Mucormicose; Administração Oral; Antifúngicos/uso terapêutico; Monitoramento de Medicamentos; Feminino; Humanos; Masculino; Pessoa de Meia-Idade; Mucormicose/tratamento farmacológico; Pandemias; Estudos Retrospectivos; SARS-CoV-2; Comprimidos; Triazóis

Palavras-chave

COVID-19; mould infection; mucormycosis; posaconazole; therapeutic drug monitoring; toxicity

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Mucormicose Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google